Download July 2016 Literature Review

Caring Ambassadors Lung Cancer Program
Literature Review, July 2016
BASIC AND APPLIED SCIENCE, PRE-CLINICAL STUDIES
SCREENING, DIAGNOSIS AND STAGING
CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES
NSCLC SURGERY
NSCLC IMMUNOTHERAPY
NSCLC CHEMOTHERAPY
NSCLC RADIOTHERAPY
SMALL CELL LUNG CANCER (SCLC)
PALLIATIVE AND SUPPORTIVE CARE
COMPLEMENTARY AND ALTERNATIVE THERAPY
MISCELLANEOUS WORKS
1-4
4-8
8-13
13-14
14-19
19-22
22-26
26-27
27
28-30
BASIC AND APPLIED SCIENCE, PRE-CLINICAL STUDIES
Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy. Liu M1, Wang H2, Liu L3,
Wang B4, Sun G5. J Transl Med. 2016 Jun 1;14(1):155. doi: 10.1186/s12967-016-0910-0.
miRNA-124 modulates lung carcinoma cell migration and invasion. Li Z, Wang X, Li W, Wu L,
Chang L, Chen H. Int J Clin Pharmacol Ther. 2016 Jun 1. [Epub ahead of print]
A combinatorial strategy for treating KRAS-mutant lung cancer. Manchado E1, Weissmueller S1,2,
Morris JP1, et al. Nature. 2016 Jun 22;534(7609):647-651. doi: 10.1038/nature18600. [Epub ahead of
print]
Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma. DiBardino DM1, Saqi A2, Elvin JA3, Greenbowe J3, Suh JH3, Miller VA3, Ali SM3,
Stoopler M4, Bulman WA5. Clin Lung Cancer. 2016 Jun 8. pii: S1525-7304(16)30133-4. doi:
10.1016/j.cllc.2016.05.017. [Epub ahead of print]
Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically
activated MAPK pathways. Zhang H1, Shao H2, Golubovskaya VM3, Chen H1, Cance W3, Adjei AA1,
Dy GK1. Br J Cancer. 2016 Jun 23. doi: 10.1038/bjc.2016.190. [Epub ahead of print]
Origin and Role of a Subset of Tumor-Associated Neutrophils with Antigen-Presenting Cell
Features in Early-Stage Human Lung Cancer. Singhal S1, Bhojnagarwala PS2, O'Brien S3, et al.
Cancer Cell. 2016 Jun 30. pii: S1535-6108(16)30226-4. doi: 10.1016/j.ccell.2016.06.001. [Epub ahead of
print]
1
Caring Ambassadors Lung Cancer Program Literature Review © 2016
SCREENING, DIAGNOSIS AND STAGING
Impact of Staging With Positron-emission Tomography (PET) and Comorbidities on Management
and Survival of American Veterans With Stage I-III Non-Small Cell Lung Cancer. Raghunathan
R1, Cease K, Troeschel S, Zhao L, Gross M, Chen G, Chopra V, Ramnath N. Am J Clin Oncol. 2016 Jun
17. [Epub ahead of print]
Mutation Yield of a 34-Gene Solid Tumor Panel in Community-Based Tumor Samples.
Sanders H1, Qu K2, Li H2, et al. Mol Diagn Ther. 2016 Jun;20(3):241-53. doi: 10.1007/s40291-0160197-0.
Safety and feasibility of prolonged bronchoscopy involving diagnosis of lung cancer, systematic
nodal staging, and fiducial marker placement in a high-risk population. Kular H1, Mudambi L1,
Lazarus DR1, Cornwell L1, Zhu A1, Casal RF1. J Thorac Dis. 2016 Jun;8(6):1132-8. doi:
10.21037/jtd.2016.04.06.
Perceptions and utilization of lung cancer screening among primary care physicians. Raz DJ1, Wu
GX1, Consunji M1, et al. J Thorac Oncol. 2016 Jun 23. pii: S1556-0864(16)30527-5. doi:
10.1016/j.jtho.2016.06.010. [Epub ahead of print]
Integration of multiple "OMIC" biomarkers: A precision medicine strategy for lung cancer.
Robles AI1, Harris CC2. Lung Cancer. 2016 Jun 14. pii: S0169-5002(16)30361-0. doi:
10.1016/j.lungcan.2016.06.003. [Epub ahead of print]
Comprehensive clinical staging for resectable lung cancer: Clinico-pathological correlations and the
role of brain MRI. Vernon J1, Andruszkiewicz N2, Schneider L1, Schieman C1, Finley CJ1, Shargall
Y1, Fahim C1, Farrokhyar F2, Hanna WC3. J Thorac Oncol. 2016 Jun 22. pii: S1556-0864(16)30520-2.
doi: 10.1016/j.jtho.2016.06.003. [Epub ahead of print]
Validation of an Electronic Program for Pathologist Training in the Interpretation of a Complex
Companion Diagnostic Immunohistochemical Assay. Dennis E1, Banks P2, Murata LB2, et al. Hum
Pathol. 2016 Jun 24. pii: S0046-8177(16)30131-9. doi: 10.1016/j.humpath.2016.06.013. [Epub ahead of
print]
Knowledge of, attitudes toward, and use of low-dose computed tomography for lung cancer
screening among family physicians.
Ersek JL1,2, Eberth JM1,3, McDonnell KK4, Strayer SM5, Sercy E3, Cartmell KB6, Friedman DB3,7.
Cancer. 2016 Jun 13. doi: 10.1002/cncr.29944. [Epub ahead of print]
Comprehensive Biomarkers for Personalized Treatment in Pulmonary Large Cell Neuroendocrine
Carcinoma: A Comparative Analysis With Adenocarcinoma. Makino T1, Mikami T2, Hata Y1, et al.
Ann Thorac Surg. 2016 Jun 28. pii: S0003-4975(16)30481-7. doi: 10.1016/j.athoracsur.2016.04.100.
[Epub ahead of print]
2
Caring Ambassadors Lung Cancer Program Literature Review © 2016
CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES
NSCLC - SURGERY
Smoking status and 30-day mortality in patients undergoing pulmonary resections. Mediratta N1,
Poullis M2. Asian Cardiovasc Thorac Ann. 2016 Jun 30. pii: 0218492316657252. [Epub ahead of print]
Comparison of treatment outcomes between single-port video-assisted thoracoscopic anatomic
segmentectomy and lobectomy for non-small cell lung cancer of early-stage: a retrospective
observational study. Lin Y1, Zheng W1, Zhu Y1, Guo Z1, Zheng B1, Chen C1. J Thorac Dis. 2016
Jun;8(6):1290-6. doi: 10.21037/jtd.2016.04.65.
For non-small cell lung cancer with T3 (central) disease, sleeve lobectomy or pneumonectomy?
Ma QL1, Guo YQ1, Shi B1, Tian YC1, Song ZY1, Liu DR1. J Thorac Dis. 2016 Jun;8(6):1227-33. doi:
10.21037/jtd.2016.04.60.
Physiologic assessment before video thoracoscopic resection for lung cancer in patients with
abnormal pulmonary function. Benattia A1, Debeaumont D1, Guyader V1, Tardif C1, Peillon C1,
Cuvelier A1, Baste JM1. J Thorac Dis. 2016 Jun;8(6):1170-8. doi: 10.21037/jtd.2016.04.38.
Outcomes of a Highly Selective Surgical Approach to Oligometastatic Lung Cancer. Johnson KK1,
Rosen JE1, Salazar MC1, Boffa DJ2. Ann Thorac Surg. 2016 Jun 23. pii: S0003-4975(16)30418-0. doi:
10.1016/j.athoracsur.2016.04.086. [Epub ahead of print]
The Outcomes of a Limited Resection for Non-Small Cell Lung Cancer Based on Differences in
Pathology. Yano M1, Yoshida J2, Koike T3, et al. World J Surg. 2016 Jun 30. [Epub ahead of print]
Recurrence and Survival After Segmentectomy in Patients With Prior Lung Resection for EarlyStage Non-Small Cell Lung Cancer. Brown LM1, Louie BE2, Jackson N3, Farivar AS4, Aye RW4,
Vallières E4. Ann Thorac Surg. 2016 Jun 24. pii: S0003-4975(16)30367-8. doi:
10.1016/j.athoracsur.2016.04.037. [Epub ahead of print]
Detection of Recurrence Patterns After Wedge Resection for Early Stage Lung Cancer: Rationale
for Radiologic Follow-Up. Billè A1, Ahmad U2, Woo KM3, Suzuki K2, Adusumilli P2, Huang J2, Jones
DR2, Rizk NP2. Ann Thorac Surg. 2016 Jun 24. pii: S0003-4975(16)30386-1. doi:
10.1016/j.athoracsur.2016.04.056. [Epub ahead of print]
Prognostic value of EGFR mutations in surgically resected pathological stage I lung
adenocarcinoma. Nishii T1,2, Yokose T2, Miyagi Y3, et al. Asia Pac J Clin Oncol. 2016 Jun 28. doi:
10.1111/ajco.12512. [Epub ahead of print]
Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung
Adenocarcinoma. Takada K1, Okamoto T2, Shoji F3, et al. J Thorac Oncol. 2016 Jun 23. pii: S15560864(16)30523-8. doi: 10.1016/j.jtho.2016.06.006. [Epub ahead of print]
NSCLC - IMMUNOTHERAPY
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
3
Caring Ambassadors Lung Cancer Program Literature Review © 2016
Gettinger S1, Rizvi NA2, Chow LQ2, et al. J Clin Oncol. 2016 Jun 27. pii: JCO669929. [Epub ahead of
print]
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment
of Advanced Non-Small-Cell Lung Cancer. Rizvi NA1, Hellmann MD2, Brahmer JR2, et al. J Clin
Oncol. 2016 Jun 27. pii: JCO669861. [Epub ahead of print]
NSCLC - CHEMOTHERAPY
Continuation maintenance therapy with S-1 in chemotherapy-naïve patients with advanced
squamous cell lung cancer. Suzuki S1, Karayama M1,2, Inui N3,4, et al. Invest New Drugs. 2016
Aug;34(4):490-6. doi: 10.1007/s10637-016-0365-4. Epub 2016 Jun 9.
Prognostic Role of Subtype Classification in Small-Sized Pathologic N0 Invasive Lung Adenocarcinoma. Yoshiya T1, Mimae T1, Tsutani Y1, et al. Ann Thorac Surg. 2016 Jun 23. pii: S00034975(16)30419-2. doi: 10.1016/j.athoracsur.2016.04.087. [Epub ahead of print]
Prognostic Impact of Missed Chemotherapy Doses During Chemoradiation Therapy for Non-Small
Cell Lung Cancer. Deek MP1, Kim S, Ahmed I, Fang BS, Zou W, Malhotra J, Aisner J, Jabbour SK.
Am J Clin Oncol. 2016 Jun 17. [Epub ahead of print]
Brain metastases from non-small cell lung cancer: radiation therapy in the era of targeted
therapies.
Khalifa J1, Amini A2, Popat S3, Gaspar LE2, Faivre-Finn C4; IASLC Advanced Radiation Technology
Committee. J Thorac Oncol. 2016 Jun 22. pii: S1556-0864(16)30519-6. doi: 10.1016/j.jtho.2016.06.002.
[Epub ahead of print]
inical data available to date and discuss future directions to improve outcome in this group of patients.
Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive NonSmall-Cell Lung Cancer. Yoshida T1, Oya Y2, Tanaka K2, et al. J Clin Oncol. 2016 Jun 27. pii:
JCO658732. [Epub ahead of print]
Efficacy of crizotinib in first-line treatment of adults with ALK-positive advanced NSCLC. Zhang
YC1,2, Zhou Q2, Wu YL2. Expert Opin Pharmacother. 2016 Jun 30. [Epub ahead of print]
Association between new-onset hypothyroidism and clinical response in patients treated with
tyrosine kinase inhibitor therapy in phase I clinical trials. Bilen MA1, Patel A2, Hess KR3, et al.
Cancer Chemother Pharmacol. 2016 Jul;78(1):167-71. doi: 10.1007/s00280-016-3073-z. Epub 2016 Jun
10.
Safety of gefitinib in non-small cell lung cancer treatment. Hsiue EH1, Lee JH1,2,3,4, Lin CC1,3,4,
Yang JC1,2,3,4. Expert Opin Drug Saf. 2016 Jul;15(7):993-1000. doi: 10.1080/14740338.2016.1192605.
Epub 2016 Jun 7.
A prospective evaluation of circulating tumor cells and cell-free DNA in EGFR mutant non-small
cell lung cancer patients treated with erlotinib on a phase II trial. Yanagita M1, Redig AJ1, Paweletz
CP2, et al. Clin Cancer Res. 2016 Jun 8. pii: clincanres.0909.2016. [Epub ahead of print]
4
Caring Ambassadors Lung Cancer Program Literature Review © 2016
Clinical Implications of the Pharmacokinetics of Crizotinib in Populations of Patients with NonSmall Cell Lung Cancer. Wang E1, Nickens DJ2, Bello A3, Khosravan R4, Amantea M5, Wilner K6,
Parivar K7, Tan W8. Clin Cancer Res. 2016 Jun 8. pii: clincanres.0536.2016. [Epub ahead of print]
Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung
Cancer Receiving Chemoradiotherapy With or Without Surgery. Yang KL1, Chang YC2, Ko HL3, et
al. Clin Lung Cancer. 2016 Jun 8. pii: S1525-7304(16)30129-2. doi: 10.1016/j.cllc.2016.05.013. [Epub
ahead of print]
NSCLC - RADIOTHERAPY
Characterizing spatiotemporal information loss in sparse-sampling-based dynamic MRI for
monitoring respiration-induced tumor motion in radiotherapy. Arai TJ1, Nofiele J2,
Madhuranthakam AJ3, Yuan Q2, Pedrosa I3, Chopra R3, Sawant A4. Med Phys. 2016 Jun;43(6):2807.
doi: 10.1118/1.4948684.
Hypofractionated Intensity-Modulated Radiotherapy for Patients With Non-Small-Cell Lung
Cancer. Pollom EL1, Qian Y1, Durkee BY1, et al. Clin Lung Cancer. 2016 Jun 8. pii: S15257304(16)30140-1. doi: 10.1016/j.cllc.2016.05.024. [Epub ahead of print]
Patterns of loco-regional relapses in contemporarily staged stage III-N2 non-small cell lung cancer
patients treated with induction chemotherapy and resection: Implications for postoperative
radiotherapy target volumes. Billiet C1, De Ruysscher D2, Peeters S3, et al. J Thorac Oncol. 2016 Jun
30. pii: S1556-0864(16)30589-5. doi: 10.1016/j.jtho.2016.05.037. [Epub ahead of print]
Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis
following Stereotactic Ablative Radiotherapy (SABR). Chaudhuri AA1, Binkley MS1, Rigdon J2, et
al. Radiother Oncol. 2016 Jun;119(3):454-60. doi: 10.1016/j.radonc.2016.05.007. Epub 2016 Jun 3.
Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV
Oncogene-Driven Lung Cancer. Campo M1, Al-Halabi H2, Khandekar M2, Shaw AT3, Sequist LV3,
Willers H4. Oncologist. 2016 Jun 27. pii: theoncologist.2015-0508. [Epub ahead of print]
Cost of Intensity-modulated Radiation Therapy for Older Stage III Lung Cancer Patients.
Kale MS1, Mhango G2, Bonomi M3, Federman A4, Sigel K5, Rosenzweig KE6, Wisnivesky JP7. Ann
Am Thorac Soc. 2016 Jun 14. [Epub ahead of print]
SMALL CELL LUNG CANCER - SCLC
PD-L1 and c-MET expression and survival in patients with small cell lung cancer. Miao L1, Lu Y1,
Xu Y1, Zhang G2, Huang Z1, Gong L1, Fan Y1. Oncotarget. 2016 Jun 1. doi: 10.18632/oncotarget.9765.
[Epub ahead of print]
Identification of Circulating Tumor DNA for the Early Detection of Small-cell Lung Cancer.
Fernandez-Cuesta L1, Perdomo S2, Avogbe PH1, et al. EBioMedicine. 2016 Jun 25. pii: S23523964(16)30289-4. doi: 10.1016/j.ebiom.2016.06.032. [Epub ahead of print]
Identification and Targeting of Long-Term Tumor-Propagating Cells in Small Cell Lung Cancer.
5
Caring Ambassadors Lung Cancer Program Literature Review © 2016
Jahchan NS1, Lim JS1, Bola B2, et al. Cell Rep. 2016 Jun 29. pii: S2211-1247(16)30761-6. doi:
10.1016/j.celrep.2016.06.021. [Epub ahead of print]
Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as secondline treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a
multicentre, open-label, randomised phase 3 trial. Goto K1, Ohe Y2, Shibata T3, et al. Lancet Oncol.
2016 Jun 13. pii: S1470-2045(16)30104-8. doi: 10.1016/S1470-2045(16)30104-8. [Epub ahead of print]
The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer. Horn L1, Reck M2,
Spigel DR3. Oncologist. 2016 Jun 27. pii: theoncologist.2015-0523. [Epub ahead of print]
Identification and Targeting of Long-Term Tumor-Propagating Cells in Small Cell Lung Cancer.
Jahchan NS1, Lim JS1, Bola B2, et al. Cell Rep. 2016 Jun 29. pii: S2211-1247(16)30761-6. doi:
10.1016/j.celrep.2016.06.021. [Epub ahead of print]
Survival and Toxicity After Cisplatin Plus Etoposide Versus Carboplatin Plus Etoposide for
Extensive-Stage Small-Cell Lung Cancer in Elderly Patients. Hatfield LA1, Huskamp HA2, Lamont
EB2. Oncol Pract. 2016 Jun 28. pii: JOPR012492. [Epub ahead of print]
Outcome and biomarker analysis from a multi-centre phase 2 study of ipilimumab in combination
with carboplatin and etoposide (ICE) as first line therapy for extensive stage small cell lung cancer.
Arriola E1, Wheater M2, Galea I3, et al. J Thorac Oncol. 2016 Jun 10. pii: S1556-0864(16)30503-2. doi:
10.1016/j.jtho.2016.05.028. [Epub ahead of print]
PALLIATIVE AND SUPPORTIVE CARE
Predictors of psychological distress in advanced cancer patients under palliative treatments. DiazFrutos D1,2,3, Baca-Garcia E1, García-Foncillas J2, López-Castroman J1,4. Eur J Cancer Care (Engl).
2016 Jul;25(4):608-15. doi: 10.1111/ecc.12521. Epub 2016 Jun 8.
Early and Intensive Dietary Counseling in Lung Cancer Patients Receiving (Chemo)RadiotherapyA Pilot Randomized Controlled Trial.
Kiss N1,2,3, Isenring E4,5, Gough K1, et al. Nutr Cancer. 2016 Jun 27:1-10. [Epub ahead of print]
Evaluation of sarcopenia in small-cell lung cancer patients by routine chest CT. Kim EY1, Kim YS2,
Park I3, Ahn HK3, Cho EK3, Jeong YM1, Kim JH1. Support Care Cancer. 2016 Jun 30. [Epub ahead of
print]
COMPLEMENTARY & ALTERNATIVE THERAPY
Moringa oleifera's Nutritious Aqueous Leaf Extract Has Anticancerous Effects by Compromising
Mitochondrial Viability in an ROS-Dependent Manner. Madi N1, Dany M2, Abdoun S3, Usta J1. J
Am Coll Nutr. 2016 Jun 17:1-10. [Epub ahead of print]
MISCELLANEOUS WORKS
6
Caring Ambassadors Lung Cancer Program Literature Review © 2016
Racial/Ethnic Disparities in Genomic Sequencing. Spratt DE1, Chan T2, Waldron L2, Speers C1, Feng
FY1, Ogunwobi OO3, Osborne JR4. JAMA Oncol. 2016 Jun 30. doi: 10.1001/jamaoncol.2016.1854.
[Epub ahead of print]
Beyond Traditional Newspaper Advertisement: Leveraging Facebook-Targeted Advertisement to
Recruit Long-Term Smokers for Research. Carter-Harris L1, Bartlett Ellis R, Warrick A, Rawl S. J
Med Internet Res. 2016 Jun 15;18(6):e117. doi: 10.2196/jmir.5502.
Impact of Race on Treatment and Survival among U.S. Veterans with Early-Stage Lung Cancer.
Williams CD1, Salama JK2, Moghanaki D3, Karas TZ4, Kelley MJ5. J Thorac Oncol. 2016 Jun 10. pii:
S1556-0864(16)30505-6. doi: 10.1016/j.jtho.2016.05.030. [Epub ahead of print]
Cancer survivors' experiences with insurance, finances, and employment: results from a multisite
study. Nekhlyudov L1, Walker R2, Ziebell R2, Rabin B3,4,5, Nutt S6,7, Chubak J2. J Cancer Surviv.
2016 Jun 9. [Epub ahead of print]
7
Caring Ambassadors Lung Cancer Program Literature Review © 2016